Biology Reference
In-Depth Information
[81] Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required
for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med
2001;193:1311-8.
[82] Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)
CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood
2002;99:3493-9.
[83] Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregu-
latory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002;196:401-6.
[84] Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+
regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-
host disease after bone marrow transplantation. Nat Med 2003;9:1144-50.
[85] Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, et al. Recipient-
type specific CD4+CD25+ regulatory T cells favor immune reconstitution and con-
trol graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest
2003;112:1688-96.
[86] Hanash AM, Levy RB. Donor CD4+CD25+ T cells promote engraftment and tolerance
following MHC-mismatched hematopoietic cell transplantation. Blood 2005;105:
1828-36.
[87] Joffre O, Gorsse N, Romagnoli P, Hudrisier D, Van Meerwijk JP. Induction of antigen-
specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes. Blood
2004;103:4216-21.
[88] Fujisaki J, Wu J, Carlson AL, Silberstein L, Putheti P, Larocca R, et al. In vivo imaging of
Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature
2011;474:216-9.
[89] Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control
of graft-versus-host disease by donor CD4(+)25(+) T cells to allow an effective graft-
versus-leukemia response. Biol Blood Marrow Transplant 2003;9:243-56.
[90] Nguyen VH, Zeiser R, Dasilva DL, Chang DS, Beilhack A, Contag CH, et al. In vivo dy-
namics of regulatory T-cell trafficking and survival predict effective strategies to control
graft-versus-host disease following allogeneic transplantation. Blood 2007;109:2649-56.
[91] Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, et al. Prevention
of graft versus host disease by inactivation of host antigen-presenting cells. Science
1999;285:412-5.
[92] Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C, et al. Host dendritic
cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol
2004;172:7393-8.
[93] Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, et al. Acute graft-versus-
host disease does not require alloantigen expression on host epithelium. Nat Med
2002;8:575-81.
[94] Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I, Jain D, et al. Donor APCs are
required for maximal GVHD but not for GVL. Nat Med 2004;10:987-92.
[95] Murai M, Yoneyama H, Ezaki T, Suematsu M, Terashima Y, Harada A, et al. Peyer's patch
is the essential site in initiating murine acute and lethal graft-versus-host reaction.
Nat Immunol 2003;4:154-60.
[96] Welniak LA, Kuprash DV, Tumanov AV, Panoskaltsis-Mortari A, Blazar BR, Sun K,
et al. Peyer patches are not required for acute graft-versus-host disease after my-
eloablative conditioning and murine allogeneic bone marrow transplantation. Blood
2006;107:410-2.
[97] Silva IA, Olkiewicz K, Askew D, Fisher JM, Chaudhary MN, Vannella KM, et al. Second-
ary lymphoid organs contribute to, but are not required for the induction of graft-
versus-host responses following allogeneic bone marrow transplantation: a shifting
paradigm for T cell allo-activation. Biol Blood Marrow Transplant 2010;16:598-611.
[98] Petrovic A, Alpdogan O, Willis LM, Eng JM, Greenberg AS, Kappel BJ, et al. LPAM (alpha
4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the develop-
ment of intestinal graft-versus-host disease. Blood 2004;103:1542-7.
[99] Dutt S, Ermann J, Tseng D, Liu YP, George TI, Fathman CG, et al. L-selectin and beta7
integrin on donor CD4 T cells are required for the early migration to host mesenteric
lymph nodes and acute colitis of graft-versus-host disease. Blood 2005;106:4009-15.
[100] Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregu-
latory T cells is antigen nonspecific. J Immunol 2000;164:183-90.
[101] Ermann J, Hoffmann P, Edinger M, Dutt S, Blankenberg FG, Higgins JP, et al. Only the
CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute
GVHD. Blood 2005;105:2220-6.
[102] Taylor PA, Panoskaltsis-Mortari A, Swedin JM, Lucas PJ, Gress RE, Levine BL, et al.
L-selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibi-
tors of GVHD and BM graft rejection. Blood 2004;104:3804-12.
266
Search WWH ::
Custom Search